The stock of Biosyent Inc. (CVE:RX) is a huge mover today! About 3,020 shares traded hands. Biosyent Inc. (CVE:RX) has risen 6.00% since October 4, 2016 and is uptrending. It has outperformed by 4.79% the S&P500.
The move comes after 8 months negative chart setup for the $106.99 million company. It was reported on Nov, 3 by Barchart.com. We have $6.67 PT which if reached, will make CVE:RX worth $14.98 million less.
More important recent Biosyent Inc. (CVE:RX) news were published by: Midasletter.com which released: “Small Cap Discoveries Editor Paul Andreola on Lingo Media Corp, Biosyent Inc …” on January 19, 2016, also Seekingalpha.com published article titled: “BioSyent: A Great Micro Cap”, Marketwired.com published: “BioSyent Pharma Announces the Canadian Launch of the First of 3 New Products …” on February 03, 2015. More interesting news about Biosyent Inc. (CVE:RX) was released by: Marketwired.com and their article: “BioSyent Signs Exclusive Distribution Agreement for Two New Cardiovascular …” with publication date: May 25, 2016.
BioSyent Inc. is a specialty pharmaceutical company. The company has a market cap of $106.99 million. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has a 28.64 P/E ratio. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.